In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $57.71 up 23.34% from its previous closing price of $46.79. In other words, the price has increased by $23.34 from its previous closing price. On the day, 7.06 million shares were traded. ARWR stock price reached its highest trading level at $59.15 during the session, while it also had its lowest trading level at $45.09.
Ratios:
For a deeper understanding of Arrowhead Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 49.96. For the most recent quarter (mrq), Quick Ratio is recorded 4.86 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31. On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when Hamilton James C sold 20,000 shares for $35.00 per share. The transaction valued at 700,000 led to the insider holds 212,122 shares of the business.
James Hamilton bought 20,000 shares of ARWR for $700,015 on Oct 01 ’25. On Sep 12 ’25, another insider, Hamilton James C, who serves as the Chief Medical Officer of the company, sold 15,000 shares for $30.00 each. As a result, the insider received 450,000 and left with 232,122 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 7978843136 and an Enterprise Value of 7691148800. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.45 while its Price-to-Book (P/B) ratio in mrq is 16.80. Its current Enterprise Value per Revenue stands at 9.273 whereas that against EBITDA is 62.901.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.29, which has changed by 1.2170572 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $46.92, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 51.17%, while the 200-Day Moving Average is calculated to be 158.08%.
Shares Statistics:
For the past three months, ARWR has traded an average of 2.30M shares per day and 3197720 over the past ten days. A total of 135.70M shares are outstanding, with a floating share count of 125.97M. Insiders hold about 7.24% of the company’s shares, while institutions hold 79.51% stake in the company. Shares short for ARWR as of 1763078400 were 11596104 with a Short Ratio of 5.03, compared to 1760486400 on 11648427. Therefore, it implies a Short% of Shares Outstanding of 11596104 and a Short% of Float of 10.82.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.84, with high estimates of $0.08 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$1.55 and -$5.93 for the fiscal current year, implying an average EPS of -$3.33. EPS for the following year is -$4.55, with 8.0 analysts recommending between -$2.98 and -$6.2.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $200.76M this quarter.It ranges from a high estimate of $425.29M to a low estimate of $18M. As of. The current estimate, Arrowhead Pharmaceuticals Inc’s year-ago sales were $2.5MFor the next quarter, 7 analysts are estimating revenue of $66.28M. There is a high estimate of $205.6M for the next quarter, whereas the lowest estimate is $1.8M.
A total of 14 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $599.56M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $388.73M. In the same quarter a year ago, actual revenue was $829.45MBased on 11 analysts’ estimates, the company’s revenue will be $286.39M in the next fiscal year. The high estimate is $440.1M and the low estimate is $114.2M.
